PHARM | 1st Gen Antipsychotics Haloperidol  episode artwork

EPISODE · Oct 28, 2025 · 41 MIN

PHARM | 1st Gen Antipsychotics Haloperidol

from STAT Stitch Deep Dive Podcast Beyond The Bedside

💊 PHARM STUDY GUIDE: HALOPERIDOL (Haldol) Class: First-generation antipsychotic 🧠 MOA (80/20): High-potency D2 receptor antagonist → ↓ mesolimbic dopamine (helps positive symptoms). D2 block in other tracts drives side effects. 🧭 Dopamine Pathways (clinical relevance):Mesolimbic: D2 block → ↓ hallucinations/delusions ✅. Nigrostriatal: D2 block → EPS/pseudoparkinsonism ⚠️. Tuberoinfundibular: D2 block → ↑ prolactin (galactorrhea, menstrual changes).📋 Indications (common): Schizophrenia; acute agitation (IM lactate); Tourette’s tics; long-term adherence with decanoate IM depot (not IV). Some off-label (e.g., delirium) are used with caution. ⚠️ Boxed/Geriatric Warning: Not approved for dementia-related psychosis; ↑ mortality and stroke risk—avoid unless benefits outweigh risks. ❤️ Cardiac Risks: QT prolongation/TdP; risk higher with IV use and high doses; correct K/Mg, monitor ECG, avoid other QT-prolongers. (IV haloperidol is not FDA-approved.) 🔥 Life-Threatening:NMS: fever, rigidity, AMS, autonomic instability → stop drug, ICU care.Severe hematologic/hepatic events (rare) → check CBC/LFTs if symptomatic. 🩺 Common/Important AEs: EPS (akathisia, dystonia, parkinsonism), TD with chronic use; sedation/orthostasis less than many SGAs due to weaker H1/α1 effects. Use AIMS to screen for TD. Treat acute dystonia/akathisia with anticholinergic or dose change.💊 Formulations & PK pearls:IM lactate: rapid control (peaks ~20–40 min).PO: peaks 2–6 h; bioavailability ~60%.IM decanoate: depot; peak ≈6 days; t½ ≈3 weeks; IM only.Metabolism: hepatic CYP2D6/CYP3A4 → active hydroxyhaloperidol. Poor 2D6 metabolizers: ↑ EPS risk. 🚫 Major Contra/Interactions (high-yield):Avoid with strong QT-prolongers (e.g., pimozide, quinidine; many azoles) → TdP. CYP inhibitors ↑ levels/QT (e.g., ketoconazole + paroxetine combo raised QTc). Ritonavir/fluvoxamine/fluoxetine can elevate levels—consider dose ↓ and ECG. CYP inducers (rifampin, carbamazepine) ↓ levels → relapse risk. Parkinson’s disease: avoid—worsens motor symptoms. 🧑‍⚕️ Nursing/Monitoring:Baseline and periodic ECG, vitals; correct electrolytes.EPS/TD checks (AIMS), fall precautions.Prolactin-related effects counseling.Reassess need regularly in older adults; document non-pharm attempts for BPSD.🎯 Top 5 NCLEX Takeaways:High-potency D2 blocker → great for positive sx, high EPS/TD risk.QT/TdP risk (esp. IV/high dose) → ECG & avoid QT drugs. Not for dementia psychosis (boxed warning). Decanoate = IM only depot; no IV. Watch for NMS—fever + rigidity = emergency

NOW PLAYING

PHARM | 1st Gen Antipsychotics Haloperidol

0:00 41:20

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of STAT Stitch Deep Dive Podcast Beyond The Bedside?

This episode is 41 minutes long.

When was this STAT Stitch Deep Dive Podcast Beyond The Bedside episode published?

This episode was published on October 28, 2025.

What is this episode about?

💊 PHARM STUDY GUIDE: HALOPERIDOL (Haldol) Class: First-generation antipsychotic 🧠 MOA (80/20): High-potency D2 receptor antagonist → ↓ mesolimbic dopamine (helps positive symptoms). D2 block in other tracts drives side effects. 🧭 Dopamine...

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this STAT Stitch Deep Dive Podcast Beyond The Bedside episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!